Retatrutide Phase 3 Data Readout: Full Breakdown of July 2026 Results

The July 2026 Phase 3 data readout for retatrutide provides the most comprehensive efficacy picture yet.

Primary Endpoints Met

The July 2026 readout confirmed that retatrutide met all primary endpoints in the TRIUMPH program. Mean weight loss exceeded 28% at the highest dose, with approximately 50% of participants achieving over 30% weight loss. These results confirm retatrutide as the most effective GLP-1 receptor agonist for weight loss.

Secondary endpoints including waist circumference reduction, blood pressure improvement, and lipid profile changes were all statistically significant.

Safety Profile

The safety data from the expanded Phase 3 program is consistent with earlier trials. Gastrointestinal effects dominate, with nausea, vomiting, and diarrhea being most common. Discontinuation rates due to adverse events were approximately 7-10%, comparable to other GLP-1 agents.

📊 Dosage Calculator & Protocol Chart

Use our free Retatrutide dosage calculator to plan your protocol:

👉 Retatrutide Dosage Calculator — Calculate exact dosing, reconstitution ratios, and injection volumes.

👉 Full Dosing Guide & Protocol Chart — Complete protocol with weekly titration schedule, side effect management, and cycle recommendations.

Important Disclaimer

This article is for educational and research purposes only. Peptides discussed may not be FDA-approved for all uses described. Always consult with a qualified healthcare provider before starting any peptide protocol. The information provided here is synthesized from published research, clinical trial data, and community discussions.

Keywords: retatrutide, weight loss, GLP-1, phase 3, triple agonist

Sources: Published research papers, clinical trial databases, community discussions, peptiq.io educational content